The investigation concerns whether MacroGenics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On April 3, 2024, MacroGenics announced Phase 2 TAMARACK interim safety data as contained in its abstract submitted to the American Society of Clinical Oncology on February 6, 2024. The Company reported that "[p]reliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability in me ...

LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On this news, MacroGenics' st ...

SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. MacroGenics, Inc. (MGNX) Investigation: On Apr. 3, 2024, MacroGenics announced Phase 2 TAMARACK interim safety data as contained in its abstract submitted to the American Society of Clinical Oncology on Feb. 6, 2024. The company said "[p]reliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves ...

About MacroGenics, Inc. ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month: Goldman Sachs 45th Annual Global Healthcare Conference (Miami Beach). MacroGenics' President & Chief Executive Officer, Scott Koe ...

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference. ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics fo ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether MacroGenics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 3, 2024 ...

Macrogenics (NASDAQ:MGNX) stock is dropping hard on Friday after the after providing investors with a clinical trial update in its latest earnings report.The news that has investors spooked today has to do with fatalities during Macrogenics’ TAMARACK study. The company reported five deaths during the clinical trial.Of these five deaths, two are considered to be unconnected to the study. That includes a case of acute myocardial infarction and one cardiac arrest. The company is currently investigating the oth ...

MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Tara Bancroft - TD Cowen Jonathan Chang - Leerink Partners Ashiq Mubarack - Citi Kaveri Pohlman - BTIG Stephen Willey - Stifel John Miller - Evercore Etzer Darout - BMO Capital Markets Mayank Mamtani - B. Riley Securities Silvan Tuerkcan - Citizens JMP Securities Kelsey Goodwin - Guggenheim Partners Peter Lawson - Barclays I would like to alert listeners that todayâs discussion will include statements about the companyâs ...

Exhibit 99.1 MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data • Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patients • Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, MD., May 9, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of (I.R.S. ...